Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

26 Oct 2022
www.biospace.com
CollaborateAcquisition
SOMERSET, N.J.--(BUSINESS WIRE)-- Sannova Analytical, LLC (“Sannova”), a leading contract research organization (“CRO”) that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey’s Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sannova is pleased to announce that Stephen Unger has joined the company as its new Chief Financial Officer. Mr. Unger is an accomplished finance executive with deep experience as both an operator and senior equity research analyst. He has served as CFO of Quotient Limited (NASDAQ: QTNT) and Circulogene Theranostics, Inc. and followed CROs and the life sciences tools and molecular diagnostics sectors for over 20 years at Bear Stearns, Lazard Capital Markets, and Needham & Company. “Jason and Steve bring new levels of client focus and operating excellence to an already stellar Sannova team,” said Michael Silvon, Executive Chairman at Sannova. “Their leadership and deep sector experience fit perfectly with the Board’s vision to create a multi-service CRO that builds upon a great Sannova legacy. I expect them to capitalize on our exceptional quality systems and customer-focused culture to drive us to even greater heights.” “I am impressed with Sannova’s culture and commitment to collaborate with customers to deliver high-quality services in the timeframe they require,” said Mr. Apter. “I look forward to partnering with Steve, the Board, and our talented team to build on this customer experience, broaden our offering, elevate our market position, and provide greater opportunities for growth to our employees.” “We are delighted to welcome Jason and Steve to Sannova,” added Roger Freeman, Board Member at Sannova and Partner at SFW Capital Partners, the majority investor in Sannova. “Their experience driving growth at several global pharmaceutical services businesses will be tremendously valuable as Sannova continues to scale through expansion of its service offering, enhancement of its sales and marketing, and pursuit of acquisitions.” About Sannova Analytical, LLC Founded in 2006, Sannova Analytical (Somerset, NJ) is a leading contract research organization that provides bioanalytical testing and analytical chemistry services for both small and large molecules to innovative pharmaceutical and biotechnology companies. Sannova is considered a trusted and quality-focused partner in drug development by customers with a strong track record of regulatory compliance. For more information, visit . About SFW Capital Partners, LP SFW Capital Partners is a private equity firm focused on building market leading companies in the industrial and life sciences technology sector. SFW partners with profitable founder- and family-owned companies and provides its capital, resources, and network to make significant growth-oriented investments and drive long-term value creation. For more information, visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.